Paeonia Lactiflora Pall. Regulates the NF-κB-NLRP3 Inflammasome Pathway to Alleviate Cholestasis in Rats

Xiao Ma,Jian-Xia Wen,Si-Jia Gao,Xuan He,Peng-Yan Li,Yu-Xue Yang,Shi-zhang Wei,Yan-Ling Zhao,Xiao-He Xiao
DOI: https://doi.org/10.1111/jphp.13008
2018-01-01
Journal of Pharmacy and Pharmacology
Abstract:OBJECTIVES:Cholestasis is a critical risk factor for severe hepatic disease or cirrhosis. The anti-inflammatory effect of Paeonia lactiflora Pall. (PLP), named Chishao in traditional Chinese medicine (TCM), on alpha-naphthylisothiocyanate (ANIT)-induced cholestasis model was tried to be elucidated in this research.METHODS:Therapeutic effect indices on hepatic function, including ALT, AST, TBIL, DBIL, ALP, TBA and γ-GT, were measured. To further investigate the protective mechanism of PLP, the mRNA and protein expression levels of NF-κB-NLRP3 inflammasome pathway were detected.RESULTS:Our results showed that compared with the model group, PLP could significantly reduce the increased serum indices such as ALT, AST, TBIL, DBIL, ALP, TBA and γ-GT induced by ANIT in a dose-dependent way. Moreover, we found that PLP downregulated the mRNA expression levels including IKK, p65, NLRP3, caspase-1 and IL-1β, especially at the large dose. Furthermore, PLP also significantly inhibited NF-κB-NLRP3 inflammasome pathway by decreasing the protein levels of p65, p-p65, p-IKK, NLRP3, caspase-1 and IL-1β.CONCLUSIONS:The results indicated that PLP could ameliorate ANIT-induced cholestasis in rats and the anti-inflammatory effect of PLP might be related to regulating NF-κB-NLRP3 inflammasome pathway. This study will provide scientific evidence for PLP as a potential drug candidate for cholestasis.
What problem does this paper attempt to address?